SEARCH

SEARCH BY CITATION

References

  • 1
    Mrowietz U, Reich K: Psoriasis – New Insights Into Pathogenesis and Treatment, Dtsch Arztebl Int 2009; 106(1–2): 119.
  • 2
  • 3
    WohlrabJ (ed): Psoriasisarthritis: in Trends Clin Exp Dermatol, Aachen, Shaker, 2005, vol 5.
  • 4
    Feyertag J, Dunky A: Arthritis psoriatica (Psoriasisarthritis), J Miner Stoffwechs 2005; 12 (4): 105109.
  • 5
    FitzGerald O, Winchester R: Psoriatic arthritis: from pathogenesis to therapy, Arthritis Research and Therapy 2009, 11: 214.
  • 6
    Winchester R: Genetics of psoriasis and psoriatic arthritis. In Psoriatic and Reactive Arthritis – A Companion to Rheumatology. Edited by RitchlinCT, FitzGeraldO. Amsterdam , The Netherlands : Elsevier; 2007.
  • 7
    Winchester R, Minevich G, Kane D, Bresnihan B, Greenberg D, FitzGerald O: Heterogenity of the psoriasis phenotype revealed by HLA class I haplotype associations in psoriatic arthritis and psoriasis. Clin Immunol 2008, 127(suppl 1): S88S89.
  • 8
    Gladman DD, Farewell VT, Kopciuk HA, Cook RJ. HLA antigens and progression in psoriatic arthritis. J Rheumatol 1998; 25: 730733.
  • 9
    Radtke MA, Mössner R, Augustin M, Reich K: Psoriasis Arthritis, Klinik, Pathogenese und Diagnostik, Der Deutsche Dermatologe 5-2007.
  • 10
    Gota C, Calabrese L: Induction of clinical autoimmune disease by therapeutic interferon-alpha. Autoimmunity 2003; 36: 511518.
  • 11
    Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973; 3(1): 5578.
  • 12
    Helliwell PS, Taylor WJ: Classification and diagnostic criteria for psoriatic arthritis. Annals of the Rheumatic Diseases 2005; 64(Supplement 2): ii3ii8.
  • 13
    Brockbank J, Stein M, Schentag C, Gladmann DD. Characteristics of dac-tylitis in psoriatic arthritis (PsA). J Rheumatol 2001; 28 (suppl 6): 1416.
  • 14
    Gladmann DD, Strand V, Mease PJ, Antoni C, Nash P, Kavanaugh A. OMERACT 7 psoriatic arthritis workshop: synopsis. Ann Rheum Dis 2005; 64 (suppl II): ii 1156.
  • 15
    Mathies U: Diagnose und Klassifikationskriterien der Osteoarthropatica psoriatica. In: WollinaU, HeinG, KopfB (Hrsg.). Psoriasis und Gelenkerkrankungen. Gustav Fischer Verlag, Jena , 1996; 11324.
  • 16
    Bizarro N, Mazzanti G, Tonutti E, Villalta D, Tozzoli R. Diagnostic accuracy of the anti-citrulline intibody assay for rheumatoid arthritis. Clin Chem 2001; 47: 108993.
  • 17
    Härle P, Hartung W, Lehmann P, Ehrenstein B, Schneider N, Müller H, Müller-Ladner U, Tarner I, Vogt T, Fleck M, Bongartz T. Detection of psoriasis arthritis with the GEPARD patient questionnaire in a dermatologic outpatient setting, Z Rheumatol. 2009 May 21.
  • 18
    Sarzi-Puttini P, Santandrea S, Boccassini L, Panni B, Caruso I. The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin Exp Rheumatol 2001; 19: S17S20.
  • 19
    Baker H, Ryan TJ. Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases. Br J Dermatol 1968; 80; 77193.
  • 20
    http://www.awmf.de Therapie der Psoriasis vulgaris Kurzfassung ICD-10 Ziffer: L40.0.
  • 21
    Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, Budiman-Mak E, Blackburn WD, Vasey FB, Mahowald ML, Cush JJ, Schumacher HR Jr, Silverman SL, Alepa FP, Luggen ME, Cohen MR, Makkena R, Haakenson CM, Ward RH, Manaster BJ, Anderson RJ, Ward JR, Henderson WG. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996; 39: 201320.
  • 22
    Combe B, Goupille P, Kuntz J, Tebib J, Leote F, Bregeon C. Sulphasalazine in psoriatic arthritis; a randomized multi-centre placebo controlled trial. Br J Rheumatol 1996; 35: 6648.
  • 23
    Rahman P, Gladmann DD, Cook RJ. The use of sulfasalazine in psoriatic arthritis: a clinic experience. J Rheumatol 1998; 25: 195761.
  • 24
    Radtke MA, Mössner R, Augustin M, Reich K: Psoriasis-Arthritis -Therapeu-tische Strategien: je früher desto besser. Der Deutsche Dermatologe 2007, 6: 407410.
  • 25
    Black RL, O'Brian WM, VanScott EJ, Aurbach R, Eisen AZ, Bunim JJ. Methotrexate therapy in psoriatic arthritis; double blind study on 21 patients. JAMA 1964; 189: 7437.
  • 26
    Liang GC, Barr WG. Long term follow-up of the use of leflunomide in recalcitrant psoriatic arthritis and psoriasis. Arthritis Rheum 2001; 44: S121.
  • 27
    Scarpa R, Manguso F, Oriente F, Peluso R, Oriente P. Leflunomide in psoriatic polyarthritis: an Italian pilot study. Arthritis Rheum 2001; 44: S92.
  • 28
    Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, Wollenhauot J, Falk FG, Mease P; Treatment of Psoriatic Arthritis Study Group. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arhtritis Rheum 2004; 50: 193950.
  • 29
    Kavanaugh A, Antoni CE, Gladman D, Wassenberg S, Zhou B, Beutler A, Keenan G, Burmester G, Furst DE, Weisman MH, Kalden JR, Smolen J, Van Der Heijde D: The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Annals of the Rheumatic Diseases 2006; 65: 103843.
  • 30
    Kavanaugh A, Krueger GG, Beutler A, Guzzo C, Zhou B, Dooley LT, Mease PJ, Gladman DD, De Vlam K, Geusens PP, Birbara C, Halter DG, Antoni C: Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 2007; 66: 498505.
  • 31
    Mease P. TNFalpha therapy in psoriatic arthritis and psoriasis. Ann Rheum Dis 2004; 63: 7558.
  • 32
    Mease PJ. Recent advances in the management of psoriatic arthritis. Curr Opin Rheumatol, 2004; 16:36670.
  • 33
    Fachinformation Remicade® (Inflixi-mab), Centocor, Leiden, Niederlande, Januar 2005.
  • 34
    Mease P, Gladmann DD; Ritchlin C, Ruderman E, Steinfeld D, Choy E, Sharp JT, Ory PA, Perdok RJ, Weinberg MA: Adalimumab therapy in patients with psoriatic arthritis: 24-week results of a phase III study. Arthritis Rheum 2004; 50: 4097.
  • 35
    Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colluci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, Van Veldhuisen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F, Fleming T. Targeted an-ticytokine therapy in patients with chronic heart failure. Circulation 2004; 109; 1594602.
  • 36
    Strober BE. Successful treatment of psoriasis and psoriatic arthritis with etanercept and methotrexate in a patient newly unresponsive to infliximab. Arch Dermatol 2004; 140: 366.